drug response News
-
Testing of a Drug Panel for effects on the gut Microbiome using RapidAIM
MedBiome’s founders reported in Microbiome the development of the RapidAIM platform to screen compounds against individual microbiomes in vitro. They tested 43 compounds (including 4 antibiotics) against 5 individual microbiomes using the RapidAIM technology. The RapidAIM workflow provides insights into microbiome absolute abundance and functional responses to drugs. ...
-
Precision therapeutics continues dedicated support to the NOCC `walk to break the silence`
Precision Therapeutics will sponsor the Pittsburgh Chapter of the National Ovarian Cancer Coalition's "Walk to Break the Silence" on Sunday, September 12, 2010. The walk, which takes place at the North Park Boathouse, is an optional 1 or 5 mile hike to benefit ovarian cancer awareness. Hoping that a great number of its employees will unite to help fortify the partnerships it has forged in ...
-
Microbiotica Announced as a Finalist in ‘Best Emerging Biotech Company’ Category at OBN Awards 2020
Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, been selected as a finalist in the ‘Best Emerging Biotech Company’ category at the OBN Awards 2020. The winners will be announced on Thursday 26th November. Microbiotica has established itself as a leading global player in its field, and most recently it has been recognised for its collaboration with ...
-
GI Innovation singed MoU with CellKey for joint biomarker research for development of next generation innovative immuno-oncology.
Joint research of biomarkers on platform technology of GI Innovation, GI-SMARTTM and SpAC9 Pipeline, AI-powered biomarker discovery platform of CellKey Prediction of drug response on next generation immuno-oncology, personalized cancer treatment effects… increasing Reliability and efficiency of treatment GI Innovation, a new innovative drug development company, announced on February ...
-
Xilis Presents Data at ESMO 2021 Demonstrating Capabilities of MicroOrganoSphere Technology for Cancer Drug Screening
Data suggests MOS platform recapitulates primary tumor tissue heterogeneity, including genomic and transcriptomic features, and microenvironment, comprising immune and stromal components MOS can be used in the evaluation of cancer drug response for chemotherapies and immunotherapies in the research setting Xilis, Inc., a pioneering company developing its MicroOrganoSphere (MOS) technology ...
By XILIS, Inc.
-
GI Innovation Signs MoU with CellKey for Biomarker Joint Research to Develop Next-generation Innovative Immuno-oncology
Joint research of biomarkers on platform technology of GI Innovation, GI-SMART™, and SpAC9 Pipeline, AI-powered biomarker discovery platform of CellKey Prediction of drug response on next-generation immuno-oncology, personalized cancer treatment effects… increasing reliability and efficiency of treatment GI Innovation, an innovative new drug development company, announced on ...
-
SEngine Precision Medicine to Present Pan Cancer Data on Predictive Value of PARIS Test at 2021 ASCO Annual Meeting
SEATTLE, April 29, 2021 (GLOBE NEWSWIRE) -- SEngine Precision Medicine, a precision oncology company that pre-tests drugs on live tumor specimens employing its CLIA certified PARIS® Test, today announced that new data from a study summarizing the predictive value of the PARIS® Test across solid tumor cancers will be presented during a poster session (abstract number 2602) at the American ...
-
SEngine Precision Medicine Presents Data at 2021 AACR Annual Meeting Demonstrating Clinical Utility and Predictive Value of PARIS Test in Ovarian Cancer
SEATTLE, April 13, 2021 (GLOBE NEWSWIRE) -- SEngine Precision Medicine, a precision oncology company that pre-tests drugs on patient-derived live tumor specimens employing its CLIA certified PARIS® Test, today presented results from an ovarian cancer study indicating strong predictive value of the PARIS® Test (abstract number 534) at the American Association for Cancer Research annual ...
-
GeneCentric Therapeutics Closes $7.5 Million Series B1 Financing
Durham, N.C., Nov. 8, 2021 – GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, today announced the closing of an oversubscribed Series B1 financing, which raised $7.5 million. Proceeds will be used to commercialize GeneCentric’s gene signatures and accelerate the growth of its pipeline of predictive response signatures for ...
-
Obsidian Therapeutics To Present Preclinical Data From cytoTIL15 Program at the 24th American Society of Gene and Cell Therapy Annual Meeting
Obsidian Therapeutics, a biotechnology company pioneering engineered cell and gene therapies, today announced that the Company will present at the upcoming 24th American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, which will be hosted virtually May 11-14, 2021. The abstract for the poster describes how Obsidian’s cytoTIL15 product (cytoTIL™ therapy engineered with ...
-
Obsidian Therapeutics to Present Preclinical Data from cytoDRiVE® Platform at the American Associate of Cancer Research (AACR) Annual Meeting 2022
Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, today announced it will present data highlighting the potential of the company’s cytoDRiVE® platform technology, which allows regulation of protein expression using small molecule drugs. The data to be presented demonstrate tight control of membrane bound or shed IL12 (a proinflammatory ...
-
SEngine Precision Medicine Presents Data Summarizing Predictive Value of PARIS Test in Breast Cancer Patients at 2020 San Antonio Breast Cancer Symposium
SEATTLE, Dec. 09, 2020 (GLOBE NEWSWIRE) -- SEngine Precision Medicine, a precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived tumor organoids, today presented data from a study summarizing the predictive value of the PARIS® Test in breast cancer tumors as a poster session (PS04/01) at the 2020 San Antonio Breast Cancer Symposium, taking place ...
-
SEngine Precision Medicine Partners with Vincere Cancer Center to Increase Access for First Responders to Get Personalized Cancer Treatments via the PARIS Test
SEATTLE, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Seattle-based Precision Oncology company SEngine Precision Medicine and Vincere Cancer Center in Scottsdale, Arizona are collaborating to provide more cancer patients with access to SEngine’s signature diagnostic test, the PARIS® Test. This collaboration, facilitated by Aspire Financial, LLC., will provide SEngine’s cutting-edge ...
-
SEngine Precision Medicine Announces New Collaboration to Bring PARIS Test to Patients with CNS Cancers
SEATTLE, Nov. 10, 2021 (GLOBE NEWSWIRE) -- SEngine Precision Medicine and Dana-Farber Cancer Institute today announced a collaboration to bring SEngine’s PARIS® Test to adult and pediatric patients with primary or metastatic solid-tumor central nervous system (CNS) cancers. The collaboration aims to provide patients and their oncologists with more information as to what therapies could ...
-
SEngine Precision Medicine closes Series A bringing total financing to $19M enabling continued advancement of personalized cancer treatments
SEATTLE, July 28, 2022 (GLOBE NEWSWIRE) -- Seattle-based Precision Oncology company SEngine Precision Medicine has now raised a total of $19M, following the recent closing of a $10M Series A2, as it continues to commercialize a platform that matches cancer patients to the right drug and also drives drug discovery. The Series A2 round was led by the Washington Research Foundation along with ...
-
PARIS Test Identified Effective Therapy for Patient with Terminal Ovarian Cancer
SEATTLE, Sept. 13, 2021 (GLOBE NEWSWIRE) -- SEngine Precision Medicine announces dramatic results for a 52-year-old patient with terminal ovarian cancer who received the PARIS® Test in early summer 2020. An interim case summary was included in SEngine’s poster presentation at the AACR 2021 annual meeting. The patient’s oncologist, Heidi Gray, MD, who specializes in ovarian cancer ...
-
Beckman Coulter Introduces Antipsychotic Drug Testing to Address Unmet Clinical Need for More Than 69 Million People Living with Serious Mental Conditions
Beckman Coulter, a global clinical diagnostics leader, announces it will introduce new antipsychotic drug tests to laboratories and clinicians to address an unmet clinical need for 69 million people with serious mental conditions worldwide. In a new agreement with Saladax Biomedical, Inc., Beckman Coulter will distribute the tests designed to measure blood levels of antipsychotic drugs ...
-
Obsidian Therapeutics To Present Preclinical Data From cytoTIL15 Program at the European Society for Medical Oncology Congress 2021
Obsidian Therapeutics, a biotechnology company pioneering engineered cell and gene therapies, today announced that the Company will present data highlighting its cytoTIL15™ program at the upcoming European Society for Medical Oncology (ESMO) Congress, which will be hosted virtually September 16-21, 2021. The abstract for the poster describes how Obsidian’s cytoTIL15 product (TIL ...
-
Obsidian Therapeutics to Present Significant Advancements to its Proprietary cytoDRiVE® Technology at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting 2022
Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, today announced it will present enhancements to its proprietary cytoDRIVE® technology during a poster presentation at the 25th ASGCT Annual Meeting. The conference is being hosted in Washington, D.C., and virtually, May 16-19, 2022. The data to be presented outline next-generation advancements ...
-
ASH 2022: Cellworks Biosimulation Study Reveals Biomarkers that Predict Response to Hypomethylating Agents and Patient Survival in MDS
Cellworks Group Inc. a leader in Precision Drug Development and Personalized Therapy Biosimulation, today announced results from a study that examined how Differentiation Scoring (DS) derived from key myeloid biomarkers in individual Myelodysplastic Syndrome (MDS) patients using the Cellworks Platform and Computational Biology Model (CBM) can predict response to Hypomethylating Agents (HMA). In ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you